Our healthcare professionals will closely monitor your progress, adjusting your treatment plan as needed to ensure both safety and long-term success
GLP-1RAs show promise in managing RA and cardiometabolic health The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with improvements in both rheumatoid arthritis (RA) disease activity and cardiovascular risk factors among people living with overweight or obesity, according to new research published in ACR Open Rheumatology
Is semaglutide the same as Ozempic
Elderly Patients Older adults may be more sensitive to side effects, particularly: Dehydration from gastrointestinal effects Falls risk from dizziness or low blood sugar Drug interactions with multiple medications Need for slower dose escalation Women of Childbearing Age Important considerations include: Both medications should be stopped 2 months before planned pregnancy Weight loss may improve fertility in some women Reliable contraception recommended during treatment Not recommended during breastfeeding The Future of Weight Loss Medications The field of obesity medicine continues to evolve rapidly
In the case of muscle, for instance, IGF1-LR3 does not cause muscle cells to get larger, but it does increase total numbers of muscle cells
Of course, Novo is not alone in its expansive R&D focus around obesity-related diseases